ANTICANCER AGENT

WIPO Patent Application WO/2017/159739

A1

Disclosed is an anticancer agent containing an NRF3 inhibitor as an active ingredient, and a cancer treatment method including a step for administering an effective amount of the NRF3 inhibitor to a mammal.

JP6966452	Method for identifying a novel protein aggregation inhibitor based on reaction kinetics
JP2002510684	[Title of Invention] Gonadotropin-releasing hormone antagonist
JP6309052	Chemoembolic therapy composition comprising an anti-angiogenic drug

WAKU TSUYOSHI (JP)
KOBAYASHI AKIRA (JP)
KATOH HIROKI (JP)
WATANABE HIDENORI (JP)
KOJI MISAKI (JP)

PCT/JP2017/010445

September 21, 2017

March 15, 2017

Click for automatic bibliography generation  

THE DOSHISHA (JP)

A61K45/00; A61K31/711; A61K31/713; A61K39/395; A61K48/00; A61P35/00; C07K16/00; C12N9/00; C12N15/09; C12N15/113

WO2009077157A1

2009-06-25

US20050048535A1

2005-03-03

KANNAN M.B. ET AL.: "Stringent Control of NFE2L3 (Nuclear Factor, Erythroid 2-Like 3; NRF3) Protein Degradation by FBW7 (F-box/WD Repeat- containing Protein 7) and Glycogen Synthase Kinase 3 (GSK3).", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 290, no. 43, 2015, pages 26292 - 26302, XP055420912, ISSN: 0021-9258
PALMA M. ET AL.: "Detection of collagen triple helix repeat containing-1 and nuclear factor (erythroid-derived 2)-like 3 in colorectal cancer.", BMC CLINICAL PATHOLOGY, vol. 2, no. 2, 9 February 2012 (2012-02-09), XP021118380, ISSN: 1472-6890
WANG C. ET AL.: "RCAN1-4 is a thyroid cancer growth and metastasis suppressor.", JCI INSIGHT, vol. 2, no. 5, 9 March 2017 (2017-03-09), pages e90651, XP055420914, ISSN: 2379-3708

SAEGUSA & PARTNERS (JP)

View/Download PDF      PDF Help

Previous Patent: MICROALLOYED BAR STEEL

Next Patent: COATING COMPOSITION, PRIMER COATING FILM, LAMINATED ANTIFOULING COATING FILM, METHOD FOR MANUFACTURI...